Reversible doxorubicin-induced congestive heart failure

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Doxorubicin hydrochloride is a vital chemotherapy drug for various cancers.
• Cardiotoxicity is a significant dose-limiting side effect, often appearing after cumulative doses exceed 500 mg/sq m.
• Late-onset cardiomyopathy, developing up to a year post-treatment, was historically considered aggressive and untreatable.

Observation:

• A patient developed a cardiotoxic reaction one year after receiving 475 mg/sq m of doxorubicin hydrochloride.
• This reaction occurred despite the cumulative dose being below the typical threshold for severe cardiotoxicity.

Findings:

• The patient's cardiotoxic reaction demonstrated responsiveness to standard cardiac therapies.
• Echocardiography and radionuclide angiocardiography confirmed the resolution of left ventricular dysfunction.

Implications:

• This case suggests that late-onset doxorubicin-induced cardiotoxicity may be treatable with conventional cardiac interventions.
• Findings challenge the notion that such cardiotoxicity is invariably progressive and unresponsive.
• This offers a potential therapeutic strategy for improving long-term outcomes in cancer survivors.